Anti-tumour necrosis factor therapy in seronegative spondyloarthritis.
Over 50% of ankylosing spondylitis patients treated with anti-tumour necrosis factor show a 50% improvement Infliximab, etanercept (and probably adalimumab) are equally effective Stable responses are maintained for two years If treatment is discontinued, almost all patients relapse Retreatment is pr...
Main Authors: | Catherine, S, Bowness, P |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2005
|
Similar Items
-
Temporomandibular joint disorders in seronegative spondyloarthritis: what a rheumatologist needs to know?
by: Vasiliki Syrmou, et al.
Published: (2023-10-01) -
Tumour necrosis factor.
by: Van Der Merwe, P
Published: (1988) -
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
by: Feldmann, M, et al.
Published: (2020) -
Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort
by: Yahya, Fariz, et al.
Published: (2017) -
The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis
by: Watts, L, et al.
Published: (2018)